Literature DB >> 16818679

Challenges of evaluating the cardiac effects of anticancer agents.

Susan E Bates, Douglas R Rosing, Tito Fojo, Richard L Piekarz.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16818679     DOI： 10.1158/1078-0432.CCR-06-1017

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  10 in total

Review 1.  Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy.

Authors:  Joanna M Brell
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

Review 2.  QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.

Authors:  Marzia Locatelli; Carmen Criscitiello; Angela Esposito; Ida Minchella; Aron Goldhirsch; Carlo Cipolla; Giuseppe Curigliano
Journal:  Target Oncol       Date:  2014-06-27       Impact factor: 4.493

3.  A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.

Authors:  Akira Fukutomi; Kiyohiko Hatake; Kaoru Matsui; Sakura Sakajiri; Tomonori Hirashima; Hiromi Tanii; Ken Kobayashi; Nobuyuki Yamamoto
Journal:  Invest New Drugs       Date:  2011-04-12       Impact factor: 3.850

4.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; H Miles Prince; Mark H Kirschbaum; Jasmine Zain; Steven L Allen; Elaine S Jaffe; Alexander Ling; Maria Turner; Cody J Peer; William D Figg; Seth M Steinberg; Sonali Smith; David Joske; Ian Lewis; Laura Hutchins; Michael Craig; A Tito Fojo; John J Wright; Susan E Bates
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

Review 5.  Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.

Authors:  Berkley E Gryder; Quaovi H Sodji; Adegboyega K Oyelere
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

Review 6.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

7.  Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.

Authors:  Jasmine Zain; Owen A O'Connor
Journal:  Invest New Drugs       Date:  2010-12-04       Impact factor: 3.850

Review 8.  Clinical Toxicities of Histone Deacetylase Inhibitors.

Authors:  Srividya Subramanian; Susan E Bates; John J Wright; Igor Espinoza-Delgado; Richard L Piekarz
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-26

9.  HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

Authors:  S Tharkar-Promod; D P Johnson; S E Bennett; E M Dennis; B G Banowsky; S S Jones; J R Shearstone; S N Quayle; C Min; M Jarpe; T Mosbruger; A D Pomicter; R R Miles; W Y Chen; K N Bhalla; P A Zweidler-McKay; D C Shrieve; M W Deininger; M B Chandrasekharan; S Bhaskara
Journal:  Leukemia       Date:  2017-06-05       Impact factor: 11.528

Review 10.  Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

Authors:  Hyungseop Kim; Woo-Baek Chung; Kyoung Im Cho; Bong-Joon Kim; Jeong-Sook Seo; Seong-Mi Park; Hak Jin Kim; Ju-Hee Lee; Eun Kyoung Kim; Ho-Joong Youn
Journal:  J Cardiovasc Ultrasound       Date:  2018-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.